Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Basic science, rationale, background and future of abatacept

Highly Accessed Review

The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis

Eric M Ruderman* and Richard M Pope

Author affiliations

Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

For all author emails, please log on.

Citation and License

Arthritis Research & Therapy 2005, 7(Suppl 2):S21-S25  doi:10.1186/ar1688

Published: 16 March 2005

Abstract

Abatacept (CTLA4–Ig) is a novel fusion protein designed to modulate the T cell co-stimulatory signal mediated through the CD28–CD80/86 pathway. Clinical trials have provided preliminary evidence of the efficacy of this compound in the treatment of rheumatoid arthritis. This review describes the molecular and biologic bases for the use of abatacept in rheumatoid arthritis and summarizes the current clinical data on its safety and effectiveness in this disease.